Skip to content
Calculator
Guide

Peptides for tendon and ligament injuries: the human evidence, ranked

Last updated: November 4, 2026 · 10 min read · By the Grey Peptides Editorial Board

A physiotherapist assists a patient in a rehabilitation session at a Vilnius clinic
Photo by Funkcinės Terapijos Centras on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Ranked by human evidence in tendon and ligament problems, the best-supported 'peptide' is collagen, mostly as a supplement taken alongside rehabilitation, and even that rests on six small studies of low certainty 3.
  • BPC-157 has one uncontrolled chart review of 16 knee patients; a 2025 orthopaedic systematic review found 35 of its 36 studies were in animals or cells 1. A 2026 orthopaedic primer found no human orthopaedic data for TB-500 and no clinical data for GHK-Cu in musculoskeletal conditions 12.
  • For patellar tendinopathy, a network meta-analysis concluded that eccentric loading exercise should remain the first-line treatment 17. In tennis elbow, steroid injections relieve pain in the short term but leave people worse off than no injection months later 18; ultrasound-guided platelet-rich plasma has shown no clear benefit over comparators in most tendon conditions 19.

Why tendons attract peptide marketing

An orthopaedic review in 2025 noted that BPC-157 is increasingly used by clinicians and athletes despite lacking FDA approval, on the strength of preclinical studies in tendon, ligament, muscle and bone injury 1. Our overview of healing peptides covers wound and gut healing more broadly; this article asks a narrower question. If you have tendinopathy, a partial tear or a ligament injury, what has actually been tested in people with that problem?

The answer depends on reading the evidence ladder honestly: cell studies and animal models first, then case series and uncontrolled reports, then randomised trials. For BPC-157, 35 of the 36 studies in that review were on the first rung 1. Our guide to reading a study explains why the rung matters.

The ranking

We ranked the products most sold for tendon and ligament injuries by the best human evidence in those injuries specifically, as of October 27, 2026. Evidence grades come from our encyclopedia and follow the rubric on our methodology page.

RankOptionBest human evidence in tendon or ligament problemsGrade
1Collagen peptides (oral, with exercise)Six small studies, low certainty: mostly oral multi-ingredient products as an add-on to rehabilitation or surgery, plus two uncontrolled injection studiesMedium
2BPC-157One uncontrolled chart review of knee injections (16 patients); 35 of 36 studies in a 2025 systematic review were preclinicalLow
3TB-500None. The human safety and wound studies quoted for it tested the full thymosin beta-4 protein, not TB-500, and none was on tendonsLow
4GHK-CuNone for tendons; its human studies are topical, on skinMedium
5BPC-157 with TB-500One rat Achilles study; the four chart-review patients given BPC-157 with a second peptide received thymosin beta-4, not TB-500Not graded as a pair

1. Collagen peptides: small studies, low certainty

Collagen peptides are fragments of collagen protein, mostly taken by mouth as supplements. They lead this ranking only because they have been tested in people with tendon problems at all. In a 2019 randomised, double-blind crossover pilot, funded by the maker of the collagen product it tested, 20 people with chronic Achilles tendinopathy followed a twice-daily calf-strengthening programme for six months and took collagen peptides or placebo for three months each. Function scores rose by 12.6 points in the first three months in those taking collagen first, against 5.3 points in those on placebo first; both groups improved further after crossing over, and no adverse events were reported 2.

A 2026 systematic review found six studies of hydrolysed collagen in tendon and ligament tears or related problems: two randomised trials of oral multi-ingredient supplements after anterior cruciate ligament reconstruction (open-label) and rotator cuff repair, the Achilles pilot above, a placebo-controlled trial in chronic ankle instability, and two uncontrolled studies of collagen peptides injected into or around shoulder tendons, one of them by the review's own first author. Collagen was associated with improvements in pain, function or imaging, but most oral products contained several ingredients, five of the six studies were judged at high risk of bias, and overall certainty was low. The authors described a cautiously positive signal as an add-on to rehabilitation or postoperative care 3. That is a modest finding. Our collagen article covers the wider evidence.

2. BPC-157: animal studies and one chart review

BPC-157 is the peptide most associated with tendon healing, and the gap between its reputation and its human evidence is wide. A 2025 systematic review written from an orthopaedic sports medicine perspective identified 36 eligible studies: 35 preclinical and one clinical 1. In animals, BPC-157 improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injury models 1.

The one clinical study is a 2021 chart review of knee injections at a single clinic. Of 16 patients reached by phone, most reported relief, but there was no control group, the outcome was recalled pain, and the chart review was retrospective 4. A 2025 two-person pilot with the same first author, at a private clinic in Florida, found intravenous BPC-157 tolerated without changes in standard blood markers 5. FDA's 2026 review of the human literature found five clinical studies of BPC-157, none a randomised trial in a tendon or ligament injury 6. It is not approved by FDA 6, it is prohibited by WADA 7, and FDA's advisory committee recommendation to allow its compounding, made in July 2026 8, had not been acted on as of October 27, 2026: it was in no category of FDA's 503A nominated-substances list (updated May 14, 2026) 9.

On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of BPC-157 under the forms, routes and conditions in its Appendix B 10. The policy is non-binding, labelled a draft and open to revision; FDA has not added it to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).

3. TB-500: the parent protein's studies, not tendon trials

TB-500 is a short fragment of thymosin beta-4. Its human evidence is the parent protein's: a randomised safety study of intravenous thymosin beta-4 in healthy volunteers, in which adverse events were infrequent 11, A 2026 orthopaedic primer found human orthopaedic data lacking for both thymosin beta-4 and TB-500 12. In a 2026 rat study of repaired Achilles tendons, the TB-500 group reached a significantly higher load to failure than controls, while the BPC-157 group's higher value did not reach significance 13. That is one animal study, and its abstract describes TB-500 as "synthetic thymosin beta-4", so which molecule the rats received is not clear from it.

4. GHK-Cu: skin studies only

GHK-Cu, a copper peptide, appears in several injury blends. Its human evidence is mostly topical and about skin: in a randomised trial after laser resurfacing in which 13 patients finished, those using copper peptide skin products rated their skin quality higher, while blinded and computer-rated outcomes did not differ 14. A 2026 orthopaedic primer found no clinical data supporting it for musculoskeletal conditions 12, and a PubMed search on October 27, 2026 found no human study of it in tendons or ligaments. The one injected human use we found was a multi-ingredient scalp formulation for hair loss that contained copper tripeptide-1 among several growth factors 15.

5. Combinations and blends

The blends sold for injuries, such as BPC-157 with TB-500 or the three- and four-peptide mixes with GHK-Cu and KPV, have the least evidence of all. The only published reports of giving any such combination we found are the rat Achilles study, where the combination added nothing over either peptide alone 13, four patients in the knee chart review who had separate injections of BPC-157 and what the paper calls thymosin-beta-4 (TB4) 4, and a 2026 report of three dental patients with nerve injury who received BPC-157 and TB-500 together with three other drugs, without a control 16. Our BPC-157 and TB-500 blend page sets out what is known about the commonest pair.

Ligaments are a separate, even thinner story

Most of the human research above concerns tendinopathy, the painful overuse condition of tendons. Ligament injuries, such as ankle sprains and tears of the anterior cruciate ligament in the knee, are different problems.

The human peptide evidence for ligaments amounts to the collagen studies in the 2026 systematic review, which included one randomised trial after anterior cruciate ligament reconstruction and an indirect study in chronic ankle instability, both of oral collagen products, the first open-label with a multi-ingredient supplement 3. We found no human study of BPC-157, TB-500 or GHK-Cu in any ligament injury. The ligament findings for BPC-157 come from preclinical models 1.

What orthopaedics relies on instead

Exercise that loads the tendon is the usual starting point. A network meta-analysis of 37 randomised trials in patellar tendinopathy found that most of the 33 treatments had been tested only once, that shockwave therapy was no better than a sham when both groups did eccentric exercise, and that the most promising options were combined with exercise; it concluded that eccentric loading should remain the first-line treatment 17. The Achilles collagen pilot above ran a six-month calf-strengthening programme in both groups 2.

Injections are a mixed picture. A large systematic review in The Lancet found that corticosteroid injections reduced pain in the short term, but in tennis elbow the effect reversed: at intermediate and long-term follow-up, people who had no injection did better 18. Platelet-rich plasma, made from a patient's own blood, has been tested in dozens of trials; a 2023 meta-analysis of 33 randomised trials of ultrasound-guided injections found no clear differences from comparators in tennis elbow, plantar fasciitis, or Achilles, rotator cuff or patellar tendinopathy, with low or very low certainty evidence 19. A 2025 meta-analysis comparing it directly with steroid injections found better pain scores at three months in rotator cuff injury but no difference in shoulder function, better results at six months in plantar fasciitis, and an earlier advantage for steroids in tennis elbow; its authors concluded that PRP's mid-term efficacy is superior to steroid injections, with long-term efficacy unverified 20.

Why the human evidence is so thin

Tendon trials are hard to read without a comparison group. In the PRP meta-analysis, patients improved from baseline after injection, but in most comparisons the control groups improved about as much 19. Outcomes such as pain and function scores are subjective, which is why the collagen review counted the lack of blinding and placebo among its main sources of bias 3. BPC-157's record is 35 preclinical studies to one clinical one in the 2025 review 1, while the treatments orthopaedic surgeons use have been tested, and sometimes found wanting, in randomised trials.

A note for athletes

BPC-157 (section S0) and TB-500 (section S2, as a thymosin beta-4 derivative) are both prohibited at all times on WADA's 2026 List 7. GHK-Cu and KPV are not named on it; S0 covers any pharmacological substance not addressed elsewhere on the List that has no current approval by a government health authority for human therapeutic use. Collagen is not on the List. Our WADA status page lists every entry.

The bottom line

If you have a tendon or ligament injury, the evidence points to a diagnosis from a clinician, a structured, progressive loading programme, patience, and caution about quick fixes, including steroid injections for chronic tendon pain. A collagen supplement alongside exercise has a small, cautiously positive evidence base. BPC-157, TB-500 and their blends have animal data and almost nothing in people. Nothing on this page is a recommendation or a dose; discuss any treatment with a clinician who knows your injury.

Frequently asked questions

What is the best peptide for tendon repair?

No peptide has been shown in randomised trials to heal tendons. Collagen peptides, mostly oral supplements taken with rehabilitation, have the most human evidence, from six small studies of low certainty. BPC-157 has one uncontrolled 16-patient chart review; TB-500 and GHK-Cu have no human tendon studies.

Does BPC-157 work for tendonitis?

It has not been tested in a controlled human trial. A 2025 orthopaedic systematic review found 35 of 36 BPC-157 studies were in animals or cells. The one human report had no comparison group.

Is TB-500 good for tendons?

There is no human study of TB-500 for tendons. Its human data are for the parent protein, thymosin beta-4, in safety, wound and eye studies. One rat study found a higher load to failure in repaired Achilles tendons with TB-500.

What actually helps tendinopathy?

For patellar tendinopathy, a 2021 network meta-analysis concluded eccentric loading should remain first-line. Steroid injections relieve pain for weeks but can be worse than no injection months later in tennis elbow, and ultrasound-guided platelet-rich plasma has shown no clear benefit over comparators in most tendon conditions.

Sources

  1. Vasireddi, N., et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 21(4), 485-495. PMID: 40756949
  2. Praet, S. F. E., et al. (2019). Oral Supplementation of Specific Collagen Peptides Combined with Calf-Strengthening Exercises Enhances Function and Reduces Pain in Achilles Tendinopathy Patients. Nutrients, 11(1). PMID: 30609761
  3. Latini, L., et al. (2026). Clinical evidence for low-molecular-weight collagen peptides in tendon and ligament tears: a systematic review with narrative synthesis. Front Med (Lausanne), 13, 1891011. PMID: 42666580
  4. Lee, E., et al. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 27(4), 8-13. PMID: 34324435
  5. Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31(5), 20-24. PMID: 40131143
  6. US FDA. BPC-157 briefing document, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (dated May 11, 2026): five clinical studies found; no approved product in any country. Read October 27, 2026. FDA
  7. World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026: S0 (names BPC-157), S2 (thymosin-beta-4 and its derivatives, e.g. TB-500). Read October 27, 2026. WADA
  8. McDermott Will & Schulte (law firm). Bulk list bound? PCAC backs majority of peptides in two-day public meeting, July 27, 2026: BPC-157 recommended 8-6 with 1 abstention. A law-firm summary; FDA has posted no tallies. Read October 27, 2026. Cited without a link.
  9. US FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Categories 1, 2 and 3). Updated May 14, 2026; read October 27, 2026: BPC-157 in no category. FDA
  10. US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register
  11. Ruff, D., et al. (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci, 1194, 223-9. PMID: 20536472
  12. Mayfield, C. K., et al. (2026). Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med, 54(1), 223-229. PMID: 41476424
  13. Biçer, O., et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 37(3), 822-837. PMID: 42542926
  14. Miller, T. R., et al. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 8(4), 252-9. PMID: 16847171
  15. Kapoor, R., et al. (2018). Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther, 20(6), 369-379. PMID: 29482481
  16. Froum, S., et al. (2026). Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health, 7, 1907109. PMID: 42876687
  17. Challoumas, D., et al. (2021). Management of patellar tendinopathy: a systematic review and network meta-analysis of randomised studies. BMJ Open Sport Exerc Med, 7(4), e001110. PMID: 34900334
  18. Coombes, B. K., et al. (2010). Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet, 376(9754), 1751-67. PMID: 20970844
  19. Masiello, F., et al. (2023). Ultrasound-guided injection of platelet-rich plasma for tendinopathies: a systematic review and meta-analysis. Blood Transfus, 21(2), 119-136. PMID: 36346880
  20. Ye, Z., et al. (2025). Platelet-rich plasma and corticosteroid injection for tendinopathy: a systematic review and meta-analysis. BMC Musculoskelet Disord, 26(1), 339. PMID: 40200209

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead